Liver/ Hepatobiliary Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center
|IRB14-0204||A Phase 2, Open Label Study of Dalantercept
plus Sorafenib in Patients with Advanced
|IRB14-0712||A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|IRB14-0595||A genotype-guided dosing study of FOLFIRABRAX in previously untreated patients with advanced gastrointestinal malignancies
|12-0033||A genotype-guided dosing study of mFOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
|IRB13-0292||A randomized, double blind, placebo-
controlled, multicenter phase III study of
regorafenib in patients with
hepatocellular carcinoma (HCC) after
|IRB13-0752||Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib.
|IRB14-0081||Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team